Botulinum Toxin Injections
J15
38 active Medicare policies list G43.509, and 3 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J15
J15 · Effective Feb 22, 2026
J6 · Effective Feb 22, 2026
JK · Effective Feb 22, 2026
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Feb 22, 2026
JM · Effective Feb 22, 2026
J5
J5 · Effective Feb 22, 2026
3 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of G43.509 |
|---|---|---|
| Visual Field Testing | Not recorded | Covered |
| Policy | Effective | Status of G43.509 |
|---|---|---|
| Peripheral Nerve Destruction for Pain Conditions | Sep 15, 2026 | Not covered |
| Policy | Effective | Status of G43.509 |
|---|---|---|
| Vyepti (Eptinezumab-Jjmr) | Sep 1, 2026 | Covered |
J5
J8 · Effective Feb 22, 2026
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 8, 2018
JF · Effective Oct 8, 2018
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J9 · Effective Oct 1, 2025
J5 · Effective Oct 1, 2025